Table 2

Associations between CYP17 genetic polymorphisms and breast cancer by menopausal status: Western New York Breast Cancer Study

Case (n [%])

Control (n [%])

Crude odds ratio (95% CI)

Adjusted odds ratio (95% CI)a


Premenopausal (n = 182)

A1/A1

58 (61)

48 (56)

1.00

1.00

A1/A2

31 (32)

28 (33)

0.92(0.48–1.73)

0.85(0.44–1.63)

A2/A2

7 (7)

10 (11)

0.58(0.21–1.64)

0.56(0.20–1.62)

Postmenopausal (n = 213)

A1/A1

51 (46)

47 (46)

1.00

1.00

A1/A2

52 (47)

43 (42)

1.10 (0.63–1.90)

0.97 (0.45–2.20)

A2/A2

8 (7)

12 (12)

0.60 (0.23–1.60)

0.45 (0.13–1.60)


a Adjusted for age, education, family history of breast cancer, body mass index, and history of benign breast disease (and age at menopause in postmenopausal women). CI, confidence interval.

Ambrosone et al. Breast Cancer Res 2003 5:R45-R51   doi:10.1186/bcr570

Open Data